Table 2. Patient characteristics in the control group (n = 330).
| n | % | |
|---|---|---|
| Gender | ||
| F | 86 | 26 |
| M | 244 | 74 |
| ECOG | ||
| 0 | 183 | 56 |
| 1 | 129 | 39 |
| 2 | 18 | 5 |
| Nephrectomy | ||
| No | 42 | 13 |
| Yes | 288 | 87 |
| Histology | ||
| Clear cell | 286 | 87 |
| Non clear cell | 44 | 13 |
| Fuhrman grade | ||
| 1 | 15 | 5 |
| 2 | 98 | 30 |
| 3 | 127 | 39 |
| 4 | 47 | 14 |
| missing | 43 | |
| MSKCC score | ||
| Good | 104 | 32 |
| Intermediate | 157 | 48 |
| Poor | 65 | 19 |
| missing | 3 | |
| Sites of Metastases | ||
| Lung | 220 | 3 |
| Lymph node | 125 | 20 |
| Liver | 62 | 10 |
| Bone | 94 | 15 |
| Thyroid | 5 | 1 |
| Other* | 115 | 19 |
| Number of targeted therapies | ||
| 1 | 164 | 49 |
| ≥2 | 166 | 51 |
| Cytokines | ||
| Yes | 82 | 25 |
| No | 248 | 75 |
*Other: adrenal, soft tissue, pleural, contralateral kidney